Related Experiment Videos
CYP2C19 gene polymorphism may be a risk factor for bronchial asthma.
Hatice Yildirim Yaroğlu1, Mukadder Calikoğlu, Lülüfer Tamer Gümüş
1Department of Biochemistry, College of Medicine, Mersin University, Mersin, Turkey. haticeyldrm@yahoo.com
Summary
The CYP2C19*2 heterozygous genotype increases bronchial asthma risk by 2.46-fold. This genetic variation may play a role in asthma development, impacting susceptibility.
Area of Science:
- Pharmacogenetics
- Respiratory Medicine
- Genetics
Background:
- Bronchial asthma is a complex respiratory condition with multifactorial etiology.
- Genetic factors are known to influence asthma susceptibility and disease severity.
- The cytochrome P450 family, specifically CYP2C19, is involved in drug metabolism and may influence inflammatory pathways relevant to asthma.
Purpose of the Study:
- To investigate the association between CYP2C19 genetic polymorphisms and the risk of developing bronchial asthma.
- To determine if specific CYP2C19 alleles contribute to asthma susceptibility in a studied population.
Main Methods:
- A case-control study involving 104 healthy individuals and 97 patients with bronchial asthma.
- Genotyping for CYP2C19*2 and CYP2C19*3 alleles was performed using real-time PCR.
- Allele detection utilized LightCycler technology and specific mutation detection kits.
Main Results:
- The CYP2C19*3 genotype was consistently found as the wild type across all participants.
- Individuals with the CYP2C19*2 heterozygous genotype exhibited a 2.46-fold increased risk of bronchial asthma compared to the CYP2C19*2 homozygous wild genotype (p = 0.01, OR = 2.46, 95% CI 1.24-4.88).
Conclusions:
- The findings suggest a potential role for the CYP2C19*2 heterozygous genotype in the pathogenesis of bronchial asthma.
- This genetic polymorphism may represent a susceptibility factor for developing the condition.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: